1. Home
  2. JANX vs LB Comparison

JANX vs LB Comparison

Compare JANX & LB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JANX
  • LB
  • Stock Information
  • Founded
  • JANX 2017
  • LB 1992
  • Country
  • JANX United States
  • LB United States
  • Employees
  • JANX N/A
  • LB N/A
  • Industry
  • JANX Biotechnology: Pharmaceutical Preparations
  • LB
  • Sector
  • JANX Health Care
  • LB
  • Exchange
  • JANX Nasdaq
  • LB NYSE
  • Market Cap
  • JANX 1.6B
  • LB 1.5B
  • IPO Year
  • JANX 2021
  • LB 2024
  • Fundamental
  • Price
  • JANX $31.05
  • LB $71.88
  • Analyst Decision
  • JANX Strong Buy
  • LB Buy
  • Analyst Count
  • JANX 7
  • LB 8
  • Target Price
  • JANX $94.29
  • LB $56.75
  • AVG Volume (30 Days)
  • JANX 975.8K
  • LB 560.2K
  • Earning Date
  • JANX 05-06-2025
  • LB 05-07-2025
  • Dividend Yield
  • JANX N/A
  • LB 0.28%
  • EPS Growth
  • JANX N/A
  • LB N/A
  • EPS
  • JANX N/A
  • LB 0.07
  • Revenue
  • JANX $10,588,000.00
  • LB $109,954,000.00
  • Revenue This Year
  • JANX N/A
  • LB $78.24
  • Revenue Next Year
  • JANX $250.58
  • LB $16.75
  • P/E Ratio
  • JANX N/A
  • LB $1,120.58
  • Revenue Growth
  • JANX 30.99
  • LB 50.90
  • 52 Week Low
  • JANX $22.52
  • LB $18.75
  • 52 Week High
  • JANX $71.71
  • LB $84.70
  • Technical
  • Relative Strength Index (RSI)
  • JANX 55.36
  • LB N/A
  • Support Level
  • JANX $27.93
  • LB N/A
  • Resistance Level
  • JANX $32.59
  • LB N/A
  • Average True Range (ATR)
  • JANX 1.97
  • LB 0.00
  • MACD
  • JANX 0.74
  • LB 0.00
  • Stochastic Oscillator
  • JANX 84.75
  • LB 0.00

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

About LB LANDBRIDGE COMPANY LLC

LandBridge Co LLC is engaged in managing land and resources to support and promote oil and natural gas development. It generates revenue streams from the use of its surface acreage, the sale of resources from land and oil and gas royalties.

Share on Social Networks: